Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: A cross-sectional study based on the National Database of Health Insurance Claims
The high proportion of patients receiving treatment for comorbidities may be partially explained by the high rate of glucocorticoid use, as approval of hydroxychloroquine for the treatment of SLE was delayed in Japan. This is the first study to ascertain the prevalence of SLE and its treatment status in Japan using the National Database, thus providing useful basic data to improve the management of the disease.
Authors
- Masakazu Matsushita (ORCID: https://orcid.org/0000-0003-3058-5778)
- Eisuke Inoue (ORCID: https://orcid.org/0000-0002-1652-7769)
- Takako Miyamae (ORCID: https://orcid.org/0000-0002-0568-1496)
- Masaki Shimizu (ORCID: https://orcid.org/0000-0003-1077-7772)
- Naoto Yokogawa (ORCID: https://orcid.org/0000-0002-7814-443X)
- Masaaki Mori (ORCID: https://orcid.org/0000-0003-2130-4866)
- Ryoko Sakai (ORCID: https://orcid.org/0000-0002-1640-1373)
- Yuzaburo Inoue (ORCID: https://orcid.org/0000-0001-5904-687X)
- Ken Yamaji (ORCID: https://orcid.org/0000-0002-0565-1828)
Institutions
- Chiba University (JP)
- Meiji Pharmaceutical University (JP)
- Juntendo University (JP)
- Chiba Hospital (JP)
- Tokyo Women's Medical University (JP)
- Tokyo Metropolitan Tama Medical Center (JP)
- SHOWA Medical University Hospital (JP)
- Institute of Science Tokyo (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1093/mr/roaf020
- Citations
- 7
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 11.68
Funders
- Ministry of Health, Labour and Welfare